

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Armistead et al.

Serial No.: Not Yet Assigned

Group Art Unit No.: 1624

Filed: October 31, 2003

Examiner: V. Balasubramanian

For: KINASE INHIBITORS

Docket No.: A-748F

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form.

In accordance with 37 CFR 1.98(d), copies of the patents, publications, pending U.S. applications, or other information listed in this information disclosure statement are not required to be provided and are not enclosed because they were previously cited by or submitted to the Office in prior application Serial No. 09/685,053, filed October 6, 2000. The present application is a continuation of this prior application which is relied upon for an earlier filing date under 35 USC 120 and the information disclosure statement submitted in the earlier application complies with 37 CFR 1.98(a)-(c).

Applicant's(s') position regarding this information and its relevancy remains unchanged.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicant(s) request(s) consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number:


EV352489239US

Date of Deposit:

October 31, 2003


I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Lynne Buchsbaum
Printed Name


Signature

PATENT APPLICATION

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Joseph W. Bullock". The signature is fluid and cursive, with the first name "Joseph" and last name "Bullock" clearly distinguishable.

Joseph W. Bullock

Attorney/Agent for Applicant(s)

Registration No.: 37,103

Phone: (805) 447-7966

Date: October 31, 2003

Please send all future correspondence to:

US Patent Operations/JWB

Dept. 4300, M/S 27-4-A

AMGEN INC.

One Amgen Center Drive

Thousand Oaks, California 91320-1799

Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.	Serial No.
	A-748F	Not Yet Assigned
	Applicant	
	Armistead et al.	
	Filing Date	Group
	October 31, 2003	1624

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CIP. CLASS	TRANSLATION	
							YES	NO
	B1	CH 261,812	9/1/49	SWITZERLAND				X
	B2	EP 0 002 341	06/13/79	EP			x	
	B3	EP 0 379 806 B1	8/1/90	EP			x	
	B1	EP 0 945 443	09/29/99	EP			x	
	B5	EP 1 040 831 A2	4/10/00	EP			x	
	B6	GB 1,390,235	4/9/75	GREAT BRITAIN			X	
	B7	WO 94/26733	11/24/94	PCT			x	
	B2	WO 95/33750	12/14/95	PCT			x	
	B9	WO 96/05177	02/22/96	PCT			x	
	B12	WO 97/19065	05/29/97	PCT			x	
	B11	WO 98/18782	05/07/98	PCT			x	
	B12	WO 99/01136	1/14/99	PCT			X	
	B13	WO 99/31073	6/24/99	PCT				X
	B18	WO 99/31121	6/24/99	PCT			X	
	B15	WO 99/41253	8/19/99	PCT			x	
	B16	WO 99/50250	10/7/99	PCT			x	
	B17	WO 99/65909	12/23/99	PCT			X	
	B18	WO 00/12485	3/9/00	PCT			x	
	B19	WO 00/27825	5/18/00	PCT			x	
	B20	WO 00/39101	7/6/00	PCT			x	
	B21	WO 00/43373	7/27/00	PCT			x	

EXAMINER:	Date Considered:
<small>EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	

Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.	Serial No.
	A-748F	Not Yet Assigned
	Applicant	
	Armistead et al.	
	Filing Date	Group
	October 31, 2003	1624

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CIB. CLASS	TRANSLATION	YES	NO
	B22	WO 00/53595	09/14/00	PCT			X	
	B23	WO 00/59892	10/12/00	PCT			X	
	B24	WO 00/63204	10/26/00	PCT			X	
	B25	WO 00/78731	12/28/00	PCT			X	
	B26	WO 01/00213	01/4/01	PCT			X	
	B27	WO 01/22938	4/5/01	PCT			X	
	B28	WO 01/29009	4/26/01	PCT			X	
	B29	WO 01/40218	6/7/01	PCT				X

EXAMINER'S
INITIALS**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	C1	Shapiro, et al., <i>Guanamine Diuretics</i> , Journal of the American Chemical Society, American Chemical Society, Washington DC, US, XP-002110860, Vol. 79, 5064-5071 (1957)
	C2	Arteaga et al. "HER (erbB) Tyrosine Kinase Inhibitors in the Treatment of Breast Cancer" Seminars in Oncology 29(No. 2 Suppl. 11) 4-10 (2002).
	C3	Bolen et al., "Leukocyte Protein Tyrosine Kinases: Potential Targets for Drug Discovery" Annu. Rev. Immunology 15: 371-404 (1997)
	C4	Cao et al., "Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models" PNAS (Proceedings of the National Academy of Sciences of the United States of America) 98:13 7443-7448.
	C5	Khandwala et al. "The effects of Insulin-like growth factors on Tumorigenesis and Neoplastic Growth" Endocrine Reviews 21(3): 215-244 (2000)
	C6	Muller et al., "Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia" Leukemia Research 26:163-168 (2002)
	C7	Raymond et al., "Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy" Drugs 60 Suppl.1: 15-23 (2000)
	C8	Scheijen et al. "Tyrosine kinase oncogenes in normal hematopoiesis and hemtological disease" Oncogene 21: 3314-3333 (2002)
	C9	Sweeney et al., "Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor" Kidney International, 57: 33-40 (2000)

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.